Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Pembrolizumab in Metastatic Solid Malignancies
NCT04609566Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by Pfizer. Started Jan 2021; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
melanomanon-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04609566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609566.